| Nov 13 |
Here's Why Inozyme Pharma (INZY) is Poised for a Turnaround After Losing -29.98% in 4 Weeks
|
| Nov 11 |
Inozyme Pharma to Present at Upcoming Investor Conferences
|
| Nov 5 |
Inozyme Pharma GAAP EPS of -$0.39 beats by $0.05
|
| Nov 5 |
Inozyme Pharma Reports Third Quarter 2024 Financial Results and Provides Business Highlights
|
| Oct 24 |
Inozyme Pharma Announces Positive Interim Data from Phase 1 SEAPORT 1 Trial of INZ-701
|
| Oct 17 |
Inozyme Pharma Announces Presentation of Interim Data from Phase 1 SEAPORT 1 Trial at the Upcoming American Society of Nephrology (ASN) Kidney Week 2024
|
| Oct 7 |
Inozyme Pharma Announces Appointment of Biopharmaceutical Commercial Leader Erik Harris to its Board of Directors
|
| Sep 26 |
Inozyme Pharma Presents New Data at the American Society for Bone and Mineral Research (ASBMR) 2024 Annual Meeting
|
| Sep 12 |
Inozyme draws buy at Stifel on lead asset
|
| Sep 12 |
This AutoNation Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
|
